Cells App Notes
Myotonic Dystrophy Type 1 CTG Repeat Length Correlates with Functional Deficit in 3D Engineered Muscle Tissues
Featuring: iPSC-derived DM1 Skeletal Muscle Myoblasts | Mantarray Platform | Nautilai Platform (Released March 2025)
Myotonic Dystrophy Type 1 (DM1) is caused by expanded CTG trinucleotide repeats in the DMPK gene, leading to RNA toxicity, disrupted splicing, and progressive muscle dysfunction.
iPSC-derived muscle tissues (EMTs) replicate DM1 disease biology, including expression of nuclear foci.
Muscle contractility inversely correlates with CTG repeat length, leading to reduced strength and impaired calcium handling.
Functional deficits were quantified using the Mantarray platform for contractile force and the Nautilai platform for calcium flux analysis.
This model provides a physiologically relevant system for studying DM1 and screening potential therapeutics to improve clinical translatability.
Mantarray™ App Notes
Functional Atrophy Induced by Dexamethasone in Primary and iPSC-derived Engineered Skeletal Muscle Tissues
Featuring: Mantarray Platform | iPSC-derived Skeletal Muscle Myoblasts | Neuromuscular Junction Model (Released February 2025)
Dexamethasone induces dose-dependent, reproducible, and reversible reductions in force generation in engineered skeletal muscle tissues (EMTs).
Both iPSC-derived and primary human EMTs showed significant atrophy, with primary cells losing all measurable contractile force at high doses.
Recovery after dexamethasone removal was slow and incomplete over a 21-day period.
The Mantarray Platform provides a robust model for studying atrophic signaling and testing potential therapeutic strategies.
Botox Potency Evaluation Using a 3D Human Neuromuscular Junction Model
Featuring: Mantarray Platform | iPSC-derived Skeletal Muscle Myoblasts | Neuromuscular Junction Model (Released February 2024)
This Application Note Covers:
Easy creation of 3D iPSC-derived Neuromuscular Junction model with automated functional output.
NMJ-specific inhibition of muscular contractility through BoNT activity.
Dose-dependent response to BoNT with EC50 calculation for potency assay applications.
A Scalable Functional Model of 3D Human Neuromuscular Junctions Using the Mantarray Platform
Featuring: Mantarray Platform | iPSC-derived Skeletal Muscle Myoblasts | Neuromuscular Junction Model (Released February 2024)
This Application Note Covers:
Facile co-culture of iPSC-derived neurons & skeletal muscle into a 3D NMJ model.
Scalable, reproducible & reliable formation of 3D human NMJs with long in vitro lifetimes.
Turnkey, longitudinal collection of NMJ functional data, backed by histological evidence.
Pre-clinical Identification of Dose-dependent Cardiac Toxicity
Featuring: Mantarray Platform (Released January 2024)
This Application Note Covers:
Turnkey scalable production of human 3D engineered heart tissues.
Label-free automated capture and analysis of functional data across 24 tissues in parallel.
In vitro validation of clinical drug toxicity and efficacy using human cell models.
Identification of optimal dosing regimens to minimize functional side-effects.
NanoSurface™ Plates App Notes
New Tools for Understanding the Role of the Extracellular Matrix in Cell Morphology: A Combined Photopatterning in Nanotopography Study
Featuring: NanoSurface Plates (Released December 2018)
In this application note, the differential impact of the chemical and structural components of the Extracellular Matrix (ECM) was investigated and compared to the structure and organization of HeLa cells.
Enhancing the Development of hPSC-neurons by Engineering the Extracellular Matrix: an MEA and Microscopy Study
Featuring: NanoSurface Plates (Released November 2018)
Nanotopographically patterned transparent multiwell microelectrode arrays (MEAs) were used to study neuronal structure, network connectivity, and sensitivity to synaptic blockers in cultured hPSCneuron monolayers.